Source: DGNews  |  Posted 8 years ago

By Eurona Earl Tilley

KYOTO, JAPAN -- October 3, 2003 -- The combined administration of ezetimibe 10 mg/dL and simvastatin 5 mg to 80 mg/dL is well tolerated and effective in allowing patients with primary hypercholesterolaemia to attain the recommended low-density lipoprotein (LDL) cholesterol levels, according to a 48-week extension study.

Luis Masana, MD, Universitat Rovira, Virgili, Spain, presented the findings here October 1st at the 13th International Symposium on Atherosclerosis. The investigation included 433 patients who had not achieved a satisfactory lipid profile on 6 or more weeks of simvastatin treatment alone.

The subject demographics included comparable lipid values